Halma, the safety, health, and environmental-technology company, has announced a significant increase in pretax profit for the six-month period ending September 30. The company attributes this growth to revenue expansion across all sectors and successful acquisitions, aligning with market expectations for full-year profit.

In comparison to the previous year, Halma's pretax profit for H1 2022 rose to £150.2 million, up from £145.5 million. Acquisitions accounted for 5.2% of this growth, compensating for adverse currency fluctuations, and a slight decline in return on sales from 19.6% to 18.7%.

Total revenue for the period reached £950.5 million, marking an increase from £875.5 million in the previous year. This growth was observed across all sectors and global markets, excluding Asia-Pacific, primarily due to weaker trends in China.

Additionally, Halma's board has declared an interim dividend of 8.41 pence per share, demonstrating their commitment to shareholders.

Looking ahead, Halma is confident in delivering strong organic constant-currency revenue growth for the fiscal year ending March. The company anticipates that its full-year adjusted pretax profit will align with market expectations, which stand at an estimated consensus of £389.0 million. In fiscal 2023, Halma reported an adjusted pretax profit of £361.3 million.

Aviva Expects to Surpass Targets and Reports Rise in Gross Written Premiums

Liontrust Asset Management Reports Losses in H1 2024

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

The Rise of Passive Investing and its Impact on Active Money Managers
News

The Rise of Passive Investing and its Impact on Active Money Managers

Passive investing is on the rise, posing challenges for active money managers and reshaping the investment landscape.

Life360 Financial Performance Report
News

Life360 Financial Performance Report

Life360 reported a positive adjusted performance with a profit of $21.9 million. The company plans to introduce partner...

ABVC Biopharma Shares Drop 15% After Exclusive Licensing Deal in China
News

ABVC Biopharma Shares Drop 15% After Exclusive Licensing Deal in China

ABVC Biopharma's shares drop 15% after entering into an exclusive licensing agreement for major depressive disorder and...

Netflix's Stock Surges on Promising Revenue Outlook
News

Netflix's Stock Surges on Promising Revenue Outlook

Netflix's stock surged 5% on Wednesday after analysts expressed confidence in its revenue growth potential through new s...